Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

• Published in: Journal of translational medicine Vol. 9; no. 1; p. 55
• Main Authors: Ido, Akio, Moriuchi, Akihiro, Numata, Masatsugu, Murayama, Toshinori, Teramukai, Satoshi, Marusawa, Hiroyuki, Yamaji, Naohisa, Setoyama, Hitoshi, Kim, Il-Deok, Chiba, Tsutomu, Higuchi, Shuji, Yokode, Masayuki, Fukushima, Masanori, Shimizu, Akira, Tsubouchi, Hirohito
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.05.2011; BioMed Central; BMC
• Subjects: Adult; Aged; Animals; Blood Pressure; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug therapy; Female; Growth factors; Hepatic Encephalopathy - drug therapy; Hepatitis - drug therapy; Hepatitis - physiopathology; Hepatitis B; Hepatocyte Growth Factor - administration & dosage; Hepatocyte Growth Factor - adverse effects; Hepatocyte Growth Factor - pharmacokinetics; Hepatocyte Growth Factor - therapeutic use; Humans; Injections, Intravenous; Kidney - pathology; Liver cells; Male; Middle Aged; Pharmacokinetics; Physiological aspects; Rats; Rats, Wistar; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; Survival Analysis; Swine; Swine, Miniature; Japan

Hepatocyte growth factor (HGF) stimulates hepatocyte proliferation, and also acts as an anti-apoptotic factor. Therefore, HGF is a potential therapeutic agent for treatment of fatal liver diseases. We performed a translational medicine protocol with recombinant human HGF (rh-HGF), including a phase...